FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
Johnson & Johnson (J&J, NYSE: JNJ) announced that the US FDA has approved the second...
Johnson & Johnson
Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
The U.S. Court of Appeals for the Third Circuit ruled against Merck & Co., Inc....
Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting
Johnson & Johnson (J&J, NYSE: JNJ) announced U.S. 510(k) regulatory clearance for MONARCH QUEST 3,...
Johnson & Johnson Secures FDA De Novo Authorization for OTTAVA™ – World’s First Table-Integrated Robotic Surgical System
Johnson & Johnson (NYSE: JNJ) announced on July 22, 2026 that the U.S. Food and...
Johnson & Johnson Reports Q2 2026 Results with 6.6% Sales Growth, Raises Full-Year Guidance
Johnson & Johnson (J&J) (J&J, NYSE: JNJ) announced second-quarter 2026 results, reporting sales growth of...
Johnson & Johnson Secures FDA Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Platform, First Single-Catheter Solution Combining Radiofrequency and Pulsed Field Ablation
Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA)...
J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line
Johnson & Johnson (J&J, NYSE: JNJ) announced on June 26, 2026, that the Committee for...
Johnson & Johnson Secures Second NMPA Approval for Akeega in BRCA2-Mutated Metastatic Prostate Cancer Following AMPLITUDE Trial Success
Johnson & Johnson (J&J, NYSE: JNJ) announced that China’s National Medical Products Administration (NMPA) has...
Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution
Johnson & Johnson (J&J, NYSE: JNJ) announced a $1+ billion investment in Jacksonville, Florida, to...
Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&J’s Stelara, Expanding Access Across Multiple Autoimmune Indications
Bio-Thera Solutions Ltd. (SHA: 688177) announced it has received marketing approval from Singapore’s Health Sciences...
J&J to Acquire Firefly Bio for $1 Billion, Adding Proprietary DAC Platform Targeting KRAS-Driven Tumors
Johnson & Johnson (J&J, NYSE: JNJ) announced today a definitive agreement to acquire Firefly Bio,...
Johnson & Johnson’s Nipocalimab (Imaavy) Demonstrates Efficacy in Phase II JASMINE Study for Systemic Lupus Erythematosus, First FcRn Blocker to Show Success in SLE
Johnson & Johnson (J&J, NYSE: JNJ) announced positive results from the Phase II JASMINE study...
J&J Secures FDA Approval for TREMFYA Label Expansion to Include Structural Joint Damage Inhibition in Psoriatic Arthritis
Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA)...
J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
Johnson & Johnson Innovative Medicine and Novartis China have announced significant leadership and organizational changes...
Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2/QX001S in Crohn’s Disease
Qyuns Therapeutics (HKG: 2509) announced that HDM3001-2/QX001S, a biosimilar to Johnson & Johnson’s autoimmune therapy...
Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform
Johnson & Johnson (J&J, NYSE: JNJ) announced a strategic alliance with the Abu Dhabi Department...
AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions
Amoy Diagnostics Co., Ltd. (SHE: 300685) announced in collaboration with Japanese partners Riken Genesis Co.,...
Johnson & Johnson Terminates Two CAR-T Development Programs Amid Portfolio Prioritization
Johnson & Johnson (J&J, NYSE: JNJ) announced the termination of development programs for JNJ-9530, a...
Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
Johnson & Johnson (J&J, NYSE: JNJ) announced that its supplemental Biologics License Application (sBLA) for...
Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology
Johnson & Johnson (J&J, NYSE: JNJ) announced on 24 April 2026 a definitive agreement to...